Using antibodies to analyze polyglutamine stretches
- PMID: 15201452
- DOI: 10.1385/1-59259-804-8:103
Using antibodies to analyze polyglutamine stretches
Abstract
Expansion of a homomeric stretch of glutamine residues beyond a critical threshold can produce neurodegenerative disease. This observation led to the idea that abnormal polyglutamine stretches can alter protein structure in ways that contribute to disease. Because they are prone to aggregation, proteins with abnormal polyglutamine expansions have been difficult to study with conventional biophysical approaches. Some of these proteins are also very large, complicating efforts to generate them in vitro or to purify them for biochemical studies. An alternative approach has been to use antibodies with known binding specificity as probes of protein folding and protein structure. Antibodies can often bind to specific protein epitopes in situ and are, therefore, one of the few tools that can be used to probe protein structure in a physiological context and in the presence of that protein's normal binding partners. However, antibodies are complex reagents, and an understanding of their binding properties, methods of use, and limitations is needed to interpret results properly. We have developed monoclonal antibodies that specifically recognize expanded polyglutamine stretches in mutant huntingtin. Here, we describe several methods for using one of these antibodies to explore the structure of abnormal polyglutamine expansions and the proteins that contain them.
Similar articles
-
Evidence for polyproline II helical structure in short polyglutamine tracts.J Mol Biol. 2006 Aug 11;361(2):362-71. doi: 10.1016/j.jmb.2006.06.044. Epub 2006 Jul 5. J Mol Biol. 2006. PMID: 16854433
-
Effects of chain length on the aggregation of model polyglutamine peptides: molecular dynamics simulations.Proteins. 2007 Jan 1;66(1):96-109. doi: 10.1002/prot.21132. Proteins. 2007. PMID: 17068817
-
Phage display screening for peptides that inhibit polyglutamine aggregation.Methods Enzymol. 2006;413:253-73. doi: 10.1016/S0076-6879(06)13014-1. Methods Enzymol. 2006. PMID: 17046401
-
Imaging polyglutamine deposits in brain tissue.Methods Enzymol. 2006;412:106-22. doi: 10.1016/S0076-6879(06)12008-X. Methods Enzymol. 2006. PMID: 17046655 Review.
-
Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases.FEBS J. 2008 Sep;275(17):4252-62. doi: 10.1111/j.1742-4658.2008.06561.x. Epub 2008 Jul 15. FEBS J. 2008. PMID: 18637947 Review.
Cited by
-
An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.Neuron. 2011 May 12;70(3):427-40. doi: 10.1016/j.neuron.2011.03.021. Neuron. 2011. PMID: 21555070 Free PMC article.
-
Polyglutamine- and temperature-dependent conformational rigidity in mutant huntingtin revealed by immunoassays and circular dichroism spectroscopy.PLoS One. 2014 Dec 2;9(12):e112262. doi: 10.1371/journal.pone.0112262. eCollection 2014. PLoS One. 2014. PMID: 25464275 Free PMC article.
-
Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.J Neurosci. 2010 Aug 4;30(31):10541-50. doi: 10.1523/JNEUROSCI.0146-10.2010. J Neurosci. 2010. PMID: 20685997 Free PMC article.
-
Control of the structural landscape and neuronal proteotoxicity of mutant Huntingtin by domains flanking the polyQ tract.Elife. 2016 Oct 18;5:e18065. doi: 10.7554/eLife.18065. Elife. 2016. PMID: 27751235 Free PMC article.
-
Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.Neuron. 2009 Dec 24;64(6):828-40. doi: 10.1016/j.neuron.2009.11.020. Neuron. 2009. PMID: 20064390 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources